Is Wegovy More Expensive Than Ozempic in the UK?

Why Wegovy and Ozempic are priced differently despite sharing an active ingredient

The MHRA licenses medicines for specific indications. Ozempic (semaglutide 0.5mg, 1mg and 2mg) holds a UK licence for type 2 diabetes management; Wegovy (semaglutide 2.4mg) holds a separate licence for chronic weight management in adults with a BMI of 30 or above, or 27 or above alongside a weight-related health condition. The clinical trial programmes behind each licence were distinct: STEP 1, published in the New England Journal of Medicine, demonstrated around 15% average weight reduction over 68 weeks at the 2.4mg dose used in Wegovy.

Manufacturers price branded medicines partly on the basis of the development costs behind each indication, the size of the eligible population, and competitive positioning. Wegovy's weight-management indication targets a much larger potential market than a diabetes-specific product, and Novo Nordisk has priced accordingly. On the NHS, Ozempic is commissioned through diabetes pathways at negotiated tariff prices that private patients never see. Wegovy, where it is available on the NHS at all, sits within specialist weight-management services under NICE appraisal TA875. Private prescriptions for Wegovy are priced by each pharmacy, there is no fixed private list.

The short answer: yes, Wegovy tends to cost more in the private market, largely because it is a higher-dose, weight-specific formulation with its own regulatory history. You can find a fuller breakdown of what drives those figures on our Wegovy cost page.

What Ozempic is actually for, and why it is not a substitute for weight-loss treatment

A question our prescribers hear regularly is whether someone can simply obtain Ozempic as a cheaper alternative to Wegovy. The clinical and legal answer is no. As the NHS medicines page for semaglutide makes clear, Ozempic is indicated for type 2 diabetes; using it for weight management alone would be off-label prescribing, which requires specific clinical justification and is not appropriate as a cost-saving workaround.

There is also a dose difference that matters clinically. The highest approved Ozempic dose for diabetes is 2mg weekly. Wegovy's maintenance dose is 2.4mg, the dose at which the STEP 1 trial generated its weight-loss evidence. Substituting one for the other is not a straightforward swap, and no responsible prescriber would do so to trim a patient's bill. If you are wondering whether Wegovy is simply the same thing as Ozempic, the answer involves some important distinctions that are worth understanding before you make any decisions about treatment. For more on how the two products relate to each other, the comparison of Wegovy and Ozempic covers the similarities and the important clinical distinctions in full.

If you are paying privately and Ozempic appears cheaper on some websites, treat that as a red flag rather than a bargain. Selling prescription medicines without a proper clinical assessment is not lawful in the UK, and the MHRA has warned repeatedly about counterfeit pens circulating via social media and unregistered sellers. Checking any online pharmacy against the GPhC register at pharmacyregulation.org takes thirty seconds and tells you immediately whether a pharmacy is legitimate.

What IS licensed for weight loss in the UK, and what that means for your options

Two injectable medicines hold UK MHRA licences for weight management in adults: Wegovy (semaglutide 2.4mg, up to 7.2mg with the newly approved higher-dose pen) and Mounjaro (tirzepatide), which works on two gut-hormone receptors rather than one. A third option (Wegovy tablets, the first oral GLP-1 medicine licensed in the UK for weight management, approved by the MHRA in June 2026) is now also available as a private prescription.

Ozempic is not on that list. Neither is Rybelsus, which is oral semaglutide licensed only for type 2 diabetes. The semaglutide overview explains how the same molecule appears across several products with meaningfully different licences. For a broader look at all approved weight-loss options, the weight-loss treatment overview sets them side by side.

If cost is a factor in your thinking, keep in mind that a legitimate private price for any of these medicines covers more than the pen kept in the fridge door. At a regulated pharmacy it includes the consultation, the prescriber's clinical review, the prescription itself and aftercare, and the peace of mind that the supply chain is verified. A price that strips those elements out is not cheaper; it is incomplete.

How semaglutide's price compares with tirzepatide, and why the gap matters

Since Eli Lilly raised Mounjaro's UK list price from around £122 to around £330 per four-week pen in September 2025, private prices across the market have shifted. Reported private Mounjaro prices now typically range from roughly £149 to £375 per month depending on the dose and provider. Wegovy sits within a similar (sometimes overlapping) band, though exact figures vary by pharmacy and dose. The Wegovy price comparison tracks what the market currently looks like in more detail.

Head-to-head trial data from SURMOUNT-5 (published in the New England Journal of Medicine, 2025) showed tirzepatide produced greater average weight reduction than semaglutide 2.4mg over 72 weeks in adults with obesity and no diabetes. Whether one medicine is the right fit over the other is a clinical question, not a price question. Both require a prescriber's assessment, a verified identity check and an honest look at your health history before treatment starts. If you want to understand which option might suit your situation, check your eligibility with our prescribers, it costs nothing and takes a few minutes.